Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1378/chest.14-0555 http://scihub22266oqcxt.onion/10.1378/chest.14-0555 C4188145!4188145 !25288000     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25288000 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25288000 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Chest 2014 ; 146 (4 ): 1102-1113 Nephropedia Template TP {{tp|p=25288000 |t=2014. Preventing ARDS: progress, promise, and pitfalls |pdf=|usr=}}{{25288000 }} gab.com Text Preventing ARDS: progress, promise, and pitfalls JO: Chest http://www.kidney.de/pget.php?&tw=1&pmid=25288000 #FOAvip Advances in critical care practice have led to a substantial decline in the incidence of ARDS over the past several years. Low tidal volume ventilation, timely resuscitation and antimicrobial administration, restrictive transfusion practices, and primary prevention of aspiration and nosocomial pneumonia have likely contributed to this reduction. Despite decades of research, there is no proven pharmacologic treatment of ARDS, and mortality from ARDS remains high. Consequently, recent initiatives have broadened the scope of lung injury research to include targeted prevention of ARDS. Prediction scores have been developed to identify patients at risk for ARDS, and clinical trials testing aspirin and inhaled budesonide/formoterol for ARDS prevention are ongoing. Future trials aimed at preventing ARDS face several key challenges. ARDS has not been validated as an end point for pivotal clinical trials, and caution is needed when testing toxic therapies that may prevent ARDS yet potentially increase mortality. Twit Text FOAVip Preventing ARDS: progress, promise, and pitfalls ????Chest http://www.kidney.de/pget.php?&tw=1&pmid=25288000 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25288000 #FOAvip English Wikipedia <ref>{{Cite pmid|25288000 }}</ref> Preventing ARDS: progress, promise, and pitfalls #MMPMID25288000 Beitler JR ; Schoenfeld DA ; Thompson BT Chest 2014[Oct]; 146 (4 ): 1102-1113 PMID25288000 show ga Advances in critical care practice have led to a substantial decline in the incidence of ARDS over the past several years. Low tidal volume ventilation, timely resuscitation and antimicrobial administration, restrictive transfusion practices, and primary prevention of aspiration and nosocomial pneumonia have likely contributed to this reduction. Despite decades of research, there is no proven pharmacologic treatment of ARDS, and mortality from ARDS remains high. Consequently, recent initiatives have broadened the scope of lung injury research to include targeted prevention of ARDS. Prediction scores have been developed to identify patients at risk for ARDS, and clinical trials testing aspirin and inhaled budesonide/formoterol for ARDS prevention are ongoing. Future trials aimed at preventing ARDS face several key challenges. ARDS has not been validated as an end point for pivotal clinical trials, and caution is needed when testing toxic therapies that may prevent ARDS yet potentially increase mortality. |Critical Care/*methods [MESH] |Humans [MESH] |Incidence [MESH] |Lung Injury/*diagnosis/prevention & control/therapy [MESH]Preventing ARDS: progress, promise, and pitfalls (epmc).pdf DeepDyve Pubget Overpricing